of the "attack/remission cycle" of AIED. Cross-reactions – Accidental damage of the inner ear by antibodies or T-cells that recognize an inner ear antigen that is similar to a bacterial or viral antigen Genetic factors – Predisposition to developing an autoimmune disorder based on genes inherited Intolerance – The immune system may not be aware of all the antigens present in the inner ear until physical damage releases some of these antigens. As a result, the immune system treats these unfamiliar antigens as foreign and mounts an immune response. Currently, the cross-reactions theory appears to be the favored mechanism of AIED pathogenesis. Diagnosis Since AIED symptoms are fairly common to many hearing loss disorders, it may be difficult to diagnose AIED without performing multiple medical tests. Some examples of these tests include: Hearing Tests for Progressive Hearing and Balance loss Audiometry (measure of hearing acuity and sound intensity) Rotatory Chair Test (determines if inner ear is responsible for balance loss) Electrocochleography (ECOG) (recording of electrical potential in inner ear due to sound) Blood Tests for General Autoimmune Diseases Erythrocyte sedimentation rate (test for inflammation) Rheumatoid Factor (indicator of autoimmune disorders) There are also blood tests specific to inner ear disorders: Anti-cochlear antibody test (testing for antibodies against cochlear cells) Lymphocyte Transformation Assay (testing whether an individual has developed a T-cell response against a certain drug) Though it has also been proposed that the use of anti heat shock protein 70 antibodies may be useful in the detection and diagnosis of AIED, there is not enough evidence to confirm the reliability of this method. Treatment AIED treatment is a rapidly changing field. Several medical therapies have been proposed in the treatment of AIED, with corticosteroid therapy being the most effective. However, corticosteroid therapy (specifically with prednisone and dexamethasone) has demonstrated limited effectiveness in some patients, suggesting the need for novel treatment methods. The goal of most AIED treatments is to administer corticosteroids over a certain period of time, re-evaluate hearing at each appointment, and eventually taper off corticosteroid administration. Ideally, patients can be tapered off with hearing fully recovered, though this is the least likely outcome. Often, tumor necrosis factor-α (TNF-α) inhibitors must be administered alongside corticosteroids to achieve a favorable outcome and eventual end to corticosteroid treatment. Recent papers have indicated that the TNF-α inhibitor, infliximab, has the potential to allow for sustained patient improvement and alleviation of symptoms. Cytotoxic